ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive
survivors

J 2021

ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors

HUBACEK, Jaroslav A., Ladislav DUŠEK, Ondřej MÁJEK, Vaclav ADAMEK, Tereza CERVINKOVA et. al.

Základní údaje

Originální název

ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors

Autoři

HUBACEK, Jaroslav A. (203 Česká republika, garant), Ladislav DUŠEK (203 Česká republika, domácí), Ondřej MÁJEK (203 Česká republika, domácí), Vaclav ADAMEK (203 Česká republika), Tereza CERVINKOVA (203 Česká republika), Dana DLOUHA (203 Česká republika) a Vera ADAMKOVA (203 Česká republika)

Vydání

Clinica Chimica Acta, AMSTERDAM, ELSEVIER SCIENCE BV, 2021, 0009-8981

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

20602 Medical laboratory technology ;

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.314

Kód RIV

RIV/00216224:14110/21:00121855

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.cca.2021.04.024

UT WoS

000659205000008

Klíčová slova anglicky

COVID-19; ACE; Polymorphism; Insertion; deletion

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 28. 6. 2021 13:50, Mgr. Tereza Miškechová

Anotace

V originále

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread from China in 2019/ 2020 to all continents. Significant geographical and ethnic differences were described, and host genetic background seems to be important for the resistance to and mortality of COVID-19. Angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism (rs4646994) is one of the candidates with the potential to affect infection symptoms and mortality. Methods: In our study, we successfully genotyped 408 SARS-CoV-2-positive COVID-19 survivors (163 asymptomatic and 245 symptomatic) and compared them with a population-based DNA bank of 2,559 subjects. Results: The frequency of ACE I/I homozygotes was significantly increased in COVID-19 patients compared with that in controls (26.2% vs. 21.2%; P = 0.02; OR [95% CI] = 1.55 [1.17-2.05]. Importantly, however, the difference was driven just by the symptomatic subjects (29.0% vs. 21.2% of the I/I homozygotes; P = 0.002; OR [95% CI] = 1.78 [1.22-2.60]). The genotype distribution of the ACE genotypes was almost identical in population controls and asymptomatic SARS-CoV-2-positive patients (P = 0.76). Conclusions: We conclude that ACE I/D polymorphism could have the potential to predict the severity of COVID19, with I/I homozygotes being at increased risk of symptomatic COVID-19.

Citovat

HUBACEK, Jaroslav A., Ladislav DUŠEK, Ondřej MÁJEK, Vaclav ADAMEK, Tereza CERVINKOVA, Dana DLOUHA a Vera ADAMKOVA. ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors. Clinica Chimica Acta. AMSTERDAM: ELSEVIER SCIENCE BV, 2021, roč. 519, AUG 2021, s. 206-209. ISSN 0009-8981. Dostupné z: https://dx.doi.org/10.1016/j.cca.2021.04.024.

@article{1779177,
   author = {Hubacek, Jaroslav A. and Dušek, Ladislav and Májek, Ondřej and Adamek, Vaclav and Cervinkova, Tereza and Dlouha, Dana and Adamkova, Vera},
   article_location = {AMSTERDAM},
   article_number = {AUG 2021},
   doi = {http://dx.doi.org/10.1016/j.cca.2021.04.024},
   keywords = {COVID-19; ACE; Polymorphism; Insertion; deletion},
   language = {eng},
   issn = {0009-8981},
   journal = {Clinica Chimica Acta},
   title = {ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors},
   url = {https://www.sciencedirect.com/science/article/pii/S0009898121001492?via%3Dihub},
   volume = {519},
   year = {2021}
}

TY  - JOUR
ID  - 1779177
AU  - Hubacek, Jaroslav A. - Dušek, Ladislav - Májek, Ondřej - Adamek, Vaclav - Cervinkova, Tereza - Dlouha, Dana - Adamkova, Vera
PY  - 2021
TI  - ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors
JF  - Clinica Chimica Acta
VL  - 519
IS  - AUG 2021
SP  - 206-209
EP  - 206-209
PB  - ELSEVIER SCIENCE BV
SN  - 00098981
KW  - COVID-19
KW  - ACE
KW  - Polymorphism
KW  - Insertion
KW  - deletion
UR  - https://www.sciencedirect.com/science/article/pii/S0009898121001492?via%3Dihub
N2  - Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread from China in 2019/ 2020 to all continents. Significant geographical and ethnic differences were described, and host genetic background seems to be important for the resistance to and mortality of COVID-19. Angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism (rs4646994) is one of the candidates with the potential to affect infection symptoms and mortality. Methods: In our study, we successfully genotyped 408 SARS-CoV-2-positive COVID-19 survivors (163 asymptomatic and 245 symptomatic) and compared them with a population-based DNA bank of 2,559 subjects. Results: The frequency of ACE I/I homozygotes was significantly increased in COVID-19 patients compared with that in controls (26.2% vs. 21.2%; P = 0.02; OR [95% CI] = 1.55 [1.17-2.05]. Importantly, however, the difference was driven just by the symptomatic subjects (29.0% vs. 21.2% of the I/I homozygotes; P = 0.002; OR [95% CI] = 1.78 [1.22-2.60]). The genotype distribution of the ACE genotypes was almost identical in population controls and asymptomatic SARS-CoV-2-positive patients (P = 0.76). Conclusions: We conclude that ACE I/D polymorphism could have the potential to predict the severity of COVID19, with I/I homozygotes being at increased risk of symptomatic COVID-19.
ER  -

HUBACEK, Jaroslav A., Ladislav DUŠEK, Ondřej MÁJEK, Vaclav ADAMEK, Tereza CERVINKOVA, Dana DLOUHA a Vera ADAMKOVA. ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors. \textit{Clinica Chimica Acta}. AMSTERDAM: ELSEVIER SCIENCE BV, 2021, roč.~519, AUG 2021, s.~206-209. ISSN~0009-8981. Dostupné z: https://dx.doi.org/10.1016/j.cca.2021.04.024.

Podrobný výpis o publikaci